Frontiers in Immunology (Sep 2022)

Selective miRNA inhibition in CD8+ cytotoxic T lymphocytes enhances HIV-1 specific cytotoxic responses

  • Nadia Madrid-Elena,
  • Nadia Madrid-Elena,
  • Sergio Serrano-Villar,
  • Sergio Serrano-Villar,
  • Sergio Serrano-Villar,
  • Carolina Gutiérrez,
  • Carolina Gutiérrez,
  • Beatriz Sastre,
  • Beatriz Sastre,
  • Matías Morín,
  • Matías Morín,
  • Laura Luna,
  • Laura Luna,
  • Laura Martín,
  • Javier Santoyo-López,
  • María Rosa López-Huertas,
  • Elena Moreno,
  • Elena Moreno,
  • María Laura García-Bermejo,
  • Miguel Ángel Moreno-Pelayo,
  • Miguel Ángel Moreno-Pelayo,
  • Santiago Moreno,
  • Santiago Moreno,
  • Santiago Moreno

DOI
https://doi.org/10.3389/fimmu.2022.998368
Journal volume & issue
Vol. 13

Abstract

Read online

miRNAs dictate relevant virus-host interactions, offering new avenues for interventions to achieve an HIV remission. We aimed to enhance HIV-specific cytotoxic responses—a hallmark of natural HIV control— by miRNA modulation in T cells. We recruited 12 participants six elite controllers and six patients with chronic HIV infection on long-term antiretroviral therapy ("progressors"). Elite controllers exhibited stronger HIV-specific cytotoxic responses than the progressors, and their CD8+T cells showed a miRNA (hsa-miR-10a-5p) significantly downregulated. When we transfected ex vivo CD8+ T cells from progressors with a synthetic miR-10a-5p inhibitor, miR-10a-5p levels decreased in 4 out of 6 progressors, correlating with an increase in HIV-specific cytotoxic responses. The effects of miR-10a-5p inhibition on HIV-specific CTL responses were modest, short-lived, and occurred before day seven after modulation. IL-4 and TNF-α levels strongly correlated with HIV-specific cytotoxic capacity. Thus, inhibition of miR-10a-5p enhanced HIV-specific CD8+ T cell capacity in progressors. Our pilot study proves the concept that miRNA modulation is a feasible strategy to combat HIV persistence by enhancing specific cytotoxic immune responses, which will inform new approaches for achieving an antiretroviral therapy-free HIV remission.

Keywords